| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 03/30/2006 | US20060067993 Topical anesthetic patch |
| 03/30/2006 | US20060067991 Non-absorbent articles for inhibiting the production of exoproteins |
| 03/30/2006 | US20060067990 Absorbent articles for inhibiting the production of exoproteins |
| 03/30/2006 | US20060067982 Encasing a core made of a siloxane-based elastomer containing dexamethasone, betamethasone, beclomethasone, and/or budesonide with a membrane made of the same or a different elastomer; and shaping the device into a shape suitable for implantation into the ear or nose |
| 03/30/2006 | US20060067975 UV cured gel and method of making |
| 03/30/2006 | US20060067966 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| 03/30/2006 | US20060067958 Pharmaceutical topical gel compositions |
| 03/30/2006 | US20060067955 2-(methacryloyloxy)ethyl 2-(acetyloxy)-4-(trifluoromethyl)benzoate; coating for synthetic biomaterials; for prostheses and other devices that are in contact with blood during use |
| 03/30/2006 | US20060067954 Lipid stabilized formulations |
| 03/30/2006 | US20060067953 Oral pharmaceutical formulations and methods for producing and using same |
| 03/30/2006 | US20060067952 Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| 03/30/2006 | US20060067925 Method and composition for inhibiting reperfusion injury in the brain |
| 03/30/2006 | US20060067911 Metered medication dose |
| 03/30/2006 | US20060067898 10 weight % terbinafine hydrochloride, 0.5 % dodecyl 2-(N,N-dimethylamino)propionate hydrochloride and 0.75 % benzyl alcohol to enhance penetration; 0.5 % polyvinylpyrrolidone, and the remainder ethanol; duel delivery through nail and skin increases topical bioavailability; onychomycosis |
| 03/30/2006 | US20060067892 Topical nanoparticulate spironolactone formulation |
| 03/30/2006 | US20060067891 Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin |
| 03/30/2006 | US20060064943 Capsule filling machine |
| 03/30/2006 | DE102004038396A1 Device (I), for coating medicinal products, comprises equipment for producing ultrasound and a vacuum chamber containing retaining means for one or more medicinal products |
| 03/30/2006 | CA2623471A1 Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| 03/30/2006 | CA2581287A1 Sustained local anesthetic composition containing bupivacaine and saib |
| 03/30/2006 | CA2581159A1 Treatment of androgen - deprivation induced osteoporosis |
| 03/30/2006 | CA2581143A1 Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
| 03/30/2006 | CA2581133A1 Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin |
| 03/30/2006 | CA2581081A1 Lyophilisate containing n-diaminomethylene-2-methyl-4,5-di-(methylsulfonyl)-benzamide |
| 03/30/2006 | CA2580890A1 Viscoelastic solution or gel formulation, and methods of treating a body site with the same |
| 03/30/2006 | CA2580889A1 Additional improvements in powder compaction and enrobing |
| 03/30/2006 | CA2580722A1 Sustained release pharmaceutical composition |
| 03/30/2006 | CA2580404A1 Pharmaceutical composition comprising roflumilast or the n-oxide of roflumilast |
| 03/30/2006 | CA2580397A1 Aqueous pharmaceutical preparation comprising roflumilast and an alkoxylated fat |
| 03/30/2006 | CA2580117A1 Coating composition |
| 03/30/2006 | CA2579673A1 Pharmaceutical composition comprising a solid dispersion with a polymer matrix containing a continuous polydextrose phase and a continuous phase of a polymer other than polydextrose |
| 03/30/2006 | CA2570521A1 Tissue matrix system |
| 03/30/2006 | CA2567741A1 Self-assembling nanoparticle drug delivery system |
| 03/29/2006 | EP1640799A1 Laser projector |
| 03/29/2006 | EP1640421A1 Labels for pharmaceutical products |
| 03/29/2006 | EP1640022A1 Menthol-containing preparation |
| 03/29/2006 | EP1640019A1 Sustained-release fine granular preparation of human growth hormone and process for producing the same |
| 03/29/2006 | EP1640008A1 A stabilized aqueous (6S)-folinic acid preparation for injection |
| 03/29/2006 | EP1640006A1 Sustained drug-relase particles and process for producing the same |
| 03/29/2006 | EP1639999A1 Nonaqueous pressure-sensitive adhesive for medicinal tape preparation for percutaneous absorption, medicinal tape preparation for percutaneous absorption, and process for producing the same |
| 03/29/2006 | EP1639998A1 Plant mucilage based lozenges against inflammatory diseases of the buccal and pharyngeal cavity |
| 03/29/2006 | EP1639997A1 Matrix for sustained, invariant and independant release of active compounds |
| 03/29/2006 | EP1639996A1 Matrix for sustained, invariant and independant release of active compounds |
| 03/29/2006 | EP1639994A2 Topical composition comprising N-acetylaldosamines or N-acetylamino acids |
| 03/29/2006 | EP1639991A2 Skin and tissue care and/or treatment composition |
| 03/29/2006 | EP1639971A1 Skin protecting compositions |
| 03/29/2006 | EP1639095A2 Method to increase protein production in culture |
| 03/29/2006 | EP1639029A2 Biodegradable poly(beta-amino esters) and uses thereof |
| 03/29/2006 | EP1639028A1 Use of an amorphous polyester as a polymer base for masticatory substances |
| 03/29/2006 | EP1639013A2 Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| 03/29/2006 | EP1638888A2 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 03/29/2006 | EP1638678A2 Method for production of enzyme granules and enzyme granules produced thus |
| 03/29/2006 | EP1638607A1 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| 03/29/2006 | EP1638597A2 Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines |
| 03/29/2006 | EP1638595A1 Freeze-dried fsh / lh formulations |
| 03/29/2006 | EP1638539A1 Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
| 03/29/2006 | EP1638538A2 Dosage form |
| 03/29/2006 | EP1638537A1 Tamsulosin core with a coating of polyvinylpyrrolidone and polyvinylacetate |
| 03/29/2006 | EP1638536A2 Implantable polymeric device for sustained release of nalmefene |
| 03/29/2006 | EP1638535A1 Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof |
| 03/29/2006 | EP1638534A1 Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix |
| 03/29/2006 | EP1638533A1 Controlled release devices with lumens |
| 03/29/2006 | EP1638532A1 Flupirtin injectable galenic form |
| 03/29/2006 | EP1638531A1 Antigen-containing microspheres for the treatment of allergies |
| 03/29/2006 | EP1638530A2 Drug polymer complexes |
| 03/29/2006 | EP1638529A2 Oral extended-release composition |
| 03/29/2006 | EP1638527A1 Composite product obtainable by cogrinding of a active principle with a copolymer n-vinyl-2-pyrrolidone/vinyl-acetate |
| 03/29/2006 | EP1638526A1 Method of treating acute coronary syndromes |
| 03/29/2006 | EP1638525A2 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 03/29/2006 | EP1638524A1 Composition and method for the treatment of water related ear disorders |
| 03/29/2006 | EP1638523A2 Formulations for coated microprojections containing non-volatile counterions |
| 03/29/2006 | EP1638522A2 Solid drug formulation and device for storage and controlled delivery thereof |
| 03/29/2006 | EP1638521A1 Transmucosal form of administration with reduced mucosal irritation |
| 03/29/2006 | EP1638519A2 Sustained release dosage forms of anesthetics for pain management |
| 03/29/2006 | EP1638492A2 Preoperative treatment of post operative pain |
| 03/29/2006 | EP1638491A2 Deployable multifunctional hemostatic agent |
| 03/29/2006 | EP1638395A1 Physical mode of action pesticide |
| 03/29/2006 | EP1443917B1 Tamsulosin tablets |
| 03/29/2006 | EP1418888B1 Breath freshening film |
| 03/29/2006 | EP1414408B1 Composition comprising paroxetine and a pharmaceutically acceptable glycyrrhizinate salt |
| 03/29/2006 | EP1347765B1 Dermatological aqueous formulations containing clindamycin and a water soluble zinc salt |
| 03/29/2006 | EP1284718B1 Occlusive transdermal therapeutic system wit a non-occlusive backing layer |
| 03/29/2006 | EP1283700B1 Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 03/29/2006 | EP1251750B1 Improved pediatric formula and methods for providing nutrition and improving tolerance |
| 03/29/2006 | EP1230267B1 Membrane translocating peptide drug delivery system |
| 03/29/2006 | EP1212601A4 Glucose biosensor |
| 03/29/2006 | EP1179342B1 Immediate release medicinal compositions for oral use |
| 03/29/2006 | EP1165050B1 Methods for fine powder formation |
| 03/29/2006 | EP1156789B1 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 03/29/2006 | EP1133282A4 Taste masking rapid release coating system |
| 03/29/2006 | EP1124567B1 Buffered compositions for dialysis |
| 03/29/2006 | EP1105105B1 Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles |
| 03/29/2006 | EP1100468B1 Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| 03/29/2006 | EP1032647B1 Preservation of sensitive biological samples by vitrification |
| 03/29/2006 | EP1012331B1 Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| 03/29/2006 | EP1005490B1 Zinc free insulin crystals for use in pulmonary compositions |
| 03/29/2006 | EP0977555B1 Pharmaceutical preparations and methods for their regional administration |
| 03/29/2006 | EP0932388B1 Dosage form and method for administering drug |
| 03/29/2006 | EP0873749B1 Jellied medicinal composition for oral administration |
| 03/29/2006 | EP0831780B1 Improved liposomal formulation |